New Immunotherapy Eliminates Cancer Without Surgery

When Maureen Sideris faced cancer for the second time in 2022, her treatment looked nothing like the grueling surgery she endured in 2008. Instead, the 71-year-old New Yorker received 45-minute infusions every three weeks for four months, and her esophageal tumor vanished completely.

No surgery. No chemotherapy. No radiation.

"It's almost like science fiction," says Sideris, who participated in a clinical trial using a drug called dostarlimab. Her only major side effect was fatigue from adrenal insufficiency.

Sideris is part of a growing wave of cancer patients benefiting from immunotherapy, a treatment approach that's finally hitting its stride after more than a century of development. The results are moving even seasoned researchers to tears.

"I get choked up and have goosebumps," says Dr. Jennifer Wargo, a surgical oncology professor at MD Anderson Cancer Center in Texas. "People are living, and living with good quality lives. We're talking about cures."

The concept is elegant. Your immune system naturally detects and destroys cells that don't belong in your body, including cancerous ones. But cancer cells are sneaky, often hiding in plain sight by disguising themselves as healthy cells.

Immunotherapy unmasks those cancer cells so your immune system can find and destroy them. Two popular approaches include CAR T-cell therapies, which supercharge your own immune cells in a lab before releasing them back into your body, and checkpoint inhibitors, which disable cancer's "off switch" that prevents immune attacks.

The treatments aren't perfect yet. Current immunotherapies work for only 20% to 40% of patients, and scientists are still figuring out why some people respond while others don't.

Why This Inspires

Researchers are attacking the response gap from every angle, and some solutions are surprisingly simple. Early studies suggest that eating high-fiber diets might improve results by changing gut bacteria. Common cholesterol medications called statins may enhance effectiveness through unexpected changes in how cells communicate. Even the time of day you receive treatment might matter, with morning doses showing better outcomes in some research.

Scientists are also combining immunotherapy with radiation, ultrasound, and other treatments to boost success rates. Every failed attempt teaches them something new about how to help the next patient.

The progress represents hope for the 90% of cancer patients whose tumors are solid masses, not blood cancers. While challenges remain, including side effects and the high cost of some treatments, researchers are solving problems that seemed impossible just years ago.

For patients like Sideris, the future that once seemed like science fiction is already here. What took nearly 100 years to develop is now saving lives, one infusion at a time.